Fulgent Genetics, Inc. Common Stock
FLGTFulgent Genetics, Inc. (FLGT) is a healthcare technology company specializing in genetic testing and related services. It provides comprehensive genetic testing solutions for healthcare providers, commercial partners, and consumers, leveraging advanced genomic analysis to assist in disease diagnosis, personalized medicine, and research. Founded in 2011, the company has evolved to become a significant player in the genetic testing industry, offering a wide array of tests in areas such as oncology, reproductive health, and rare diseases.
Company News
Law firm Lowey Dannenberg is investigating Fulgent Genetics Inc. for potential violations of federal securities laws following the company's February 27, 2026 earnings report, which showed full year 2025 revenue of $322.7 million falling slightly short of updated guidance and sequential fourth quarter revenue decline. The firm is encouraging inve...
Kirby McInerney LLP is investigating Fulgent Genetics Inc. for potential securities law violations following a significant stock price decline. On February 27, 2026, Fulgent reported lower-than-expected 2026 guidance due to its largest customer moving work in-house, causing shares to drop 38.1% from $24.76 to $15.33. The law firm is seeking inves...
The global esoteric testing market is projected to grow from $27.52 billion in 2025 to $41.56 billion by 2031 at a 7.11% CAGR, driven by rising chronic disease rates, personalized medicine demand, and liquid biopsy adoption. However, stringent regulatory frameworks and reimbursement pressures pose significant challenges to market expansion.
Fulgent Genetics reported Q2 earnings that exceeded analyst expectations, with revenue of $82 million, representing a 15% year-over-year increase, despite a 56% decrease in adjusted net income.
Law firm Bragar Eagel & Squire is investigating potential securities law violations by GoHealth, Semler Scientific, ADTRAN, and Fulgent Genetics, following DOJ investigations and financial reporting issues.
